| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 82 | 2023 | 2768 | 15.440 |
Why?
|
| Mastectomy | 46 | 2023 | 228 | 15.140 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2022 | 154 | 8.190 |
Why?
|
| Carcinoma, Lobular | 18 | 2019 | 78 | 6.770 |
Why?
|
| Surgeons | 10 | 2022 | 192 | 4.870 |
Why?
|
| Mastectomy, Segmental | 16 | 2023 | 89 | 4.190 |
Why?
|
| Mammaplasty | 10 | 2023 | 101 | 3.480 |
Why?
|
| Prophylactic Mastectomy | 8 | 2020 | 12 | 3.260 |
Why?
|
| Neoadjuvant Therapy | 8 | 2019 | 274 | 3.230 |
Why?
|
| Neoplasm Staging | 25 | 2019 | 1889 | 2.860 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 110 | 2.660 |
Why?
|
| Quality Indicators, Health Care | 5 | 2021 | 132 | 2.330 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 199 | 2.250 |
Why?
|
| Surgical Oncology | 4 | 2020 | 16 | 2.230 |
Why?
|
| Receptors, Estrogen | 10 | 2022 | 377 | 2.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2021 | 55 | 2.170 |
Why?
|
| Cancer Care Facilities | 3 | 2020 | 26 | 2.120 |
Why?
|
| Radiation Oncology | 3 | 2021 | 121 | 2.100 |
Why?
|
| Databases, Factual | 18 | 2018 | 763 | 2.050 |
Why?
|
| Prognosis | 25 | 2020 | 3562 | 2.020 |
Why?
|
| Accreditation | 3 | 2019 | 55 | 2.010 |
Why?
|
| Female | 85 | 2023 | 42787 | 2.010 |
Why?
|
| Middle Aged | 62 | 2022 | 24187 | 1.960 |
Why?
|
| Time-to-Treatment | 3 | 2021 | 75 | 1.940 |
Why?
|
| Practice Guidelines as Topic | 7 | 2019 | 1036 | 1.850 |
Why?
|
| Breast Neoplasms, Male | 2 | 2022 | 31 | 1.830 |
Why?
|
| Guideline Adherence | 4 | 2018 | 215 | 1.770 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 1226 | 1.740 |
Why?
|
| Follow-Up Studies | 21 | 2020 | 3592 | 1.720 |
Why?
|
| Aged, 80 and over | 33 | 2018 | 6246 | 1.680 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 446 | 1.660 |
Why?
|
| Aged | 48 | 2021 | 17610 | 1.650 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 285 | 1.630 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.580 |
Why?
|
| Humans | 94 | 2023 | 81631 | 1.580 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.540 |
Why?
|
| Nipples | 6 | 2022 | 36 | 1.500 |
Why?
|
| Receptor, ErbB-2 | 5 | 2019 | 198 | 1.400 |
Why?
|
| Thoracic Wall | 2 | 2018 | 22 | 1.390 |
Why?
|
| Lymph Nodes | 4 | 2018 | 510 | 1.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2348 | 1.300 |
Why?
|
| Adult | 43 | 2022 | 24856 | 1.280 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 558 | 1.240 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 154 | 1.220 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 516 | 1.220 |
Why?
|
| United States | 26 | 2022 | 6212 | 1.200 |
Why?
|
| Ergonomics | 3 | 2022 | 20 | 1.200 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1623 | 1.160 |
Why?
|
| Decision Making | 4 | 2019 | 604 | 1.150 |
Why?
|
| Breast | 6 | 2021 | 273 | 1.110 |
Why?
|
| Axilla | 11 | 2021 | 92 | 1.100 |
Why?
|
| Retrospective Studies | 23 | 2020 | 7664 | 1.100 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 163 | 1.090 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1413 | 1.090 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 247 | 1.070 |
Why?
|
| Survival Rate | 12 | 2018 | 1822 | 1.050 |
Why?
|
| Carcinoma | 2 | 2017 | 426 | 0.940 |
Why?
|
| Brachytherapy | 2 | 2014 | 120 | 0.930 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 34 | 0.900 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 2316 | 0.890 |
Why?
|
| Medical Overuse | 2 | 2019 | 36 | 0.880 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 628 | 0.880 |
Why?
|
| Neoplasm Grading | 10 | 2018 | 323 | 0.850 |
Why?
|
| Oncologists | 1 | 2021 | 33 | 0.820 |
Why?
|
| Quality of Health Care | 3 | 2018 | 366 | 0.800 |
Why?
|
| Burnout, Professional | 1 | 2021 | 81 | 0.750 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 335 | 0.750 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 468 | 0.730 |
Why?
|
| Age Factors | 9 | 2018 | 1805 | 0.730 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 146 | 0.710 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 51 | 0.710 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 68 | 0.710 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.710 |
Why?
|
| Patient Satisfaction | 4 | 2016 | 434 | 0.700 |
Why?
|
| Patient Selection | 6 | 2019 | 667 | 0.690 |
Why?
|
| Reoperation | 5 | 2015 | 575 | 0.680 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 302 | 0.670 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 286 | 0.670 |
Why?
|
| Consensus | 2 | 2016 | 304 | 0.670 |
Why?
|
| Patient Care | 1 | 2019 | 90 | 0.670 |
Why?
|
| Patient Transfer | 1 | 2018 | 86 | 0.660 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 139 | 0.660 |
Why?
|
| Genes, BRCA2 | 3 | 2016 | 151 | 0.660 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 148 | 0.660 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 13 | 0.650 |
Why?
|
| Genes, BRCA1 | 3 | 2016 | 189 | 0.650 |
Why?
|
| Young Adult | 12 | 2021 | 5761 | 0.640 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 29 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 222 | 0.640 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 87 | 0.620 |
Why?
|
| Patient Preference | 4 | 2019 | 104 | 0.610 |
Why?
|
| Logistic Models | 7 | 2017 | 1117 | 0.610 |
Why?
|
| Postoperative Complications | 7 | 2016 | 2104 | 0.600 |
Why?
|
| Societies, Medical | 2 | 2019 | 568 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 493 | 0.550 |
Why?
|
| Quality of Life | 4 | 2019 | 1405 | 0.550 |
Why?
|
| Prospective Studies | 8 | 2022 | 3978 | 0.550 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 138 | 0.530 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 341 | 0.490 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 116 | 0.470 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1429 | 0.470 |
Why?
|
| Length of Stay | 3 | 2015 | 659 | 0.460 |
Why?
|
| Melanoma | 2 | 2009 | 432 | 0.460 |
Why?
|
| Receptors, Notch | 2 | 2010 | 119 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 514 | 0.440 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 181 | 0.440 |
Why?
|
| Registries | 1 | 2014 | 652 | 0.420 |
Why?
|
| Workload | 2 | 2022 | 125 | 0.400 |
Why?
|
| Receptor, Notch1 | 2 | 2010 | 82 | 0.400 |
Why?
|
| Patient Readmission | 1 | 2014 | 296 | 0.400 |
Why?
|
| Operating Rooms | 2 | 2022 | 120 | 0.400 |
Why?
|
| Adolescent | 7 | 2021 | 8766 | 0.390 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2008 | 3 | 0.360 |
Why?
|
| Patients | 2 | 2023 | 92 | 0.360 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 539 | 0.340 |
Why?
|
| Breast Diseases | 1 | 2008 | 96 | 0.340 |
Why?
|
| Quality Control | 2 | 2019 | 113 | 0.330 |
Why?
|
| Breast Implantation | 3 | 2016 | 11 | 0.320 |
Why?
|
| Calcinosis | 1 | 2008 | 232 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 647 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2019 | 804 | 0.310 |
Why?
|
| SEER Program | 3 | 2017 | 180 | 0.300 |
Why?
|
| Risk Factors | 6 | 2019 | 5185 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 830 | 0.290 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 968 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3121 | 0.270 |
Why?
|
| Risk Assessment | 4 | 2020 | 2182 | 0.270 |
Why?
|
| Health Care Surveys | 2 | 2018 | 276 | 0.270 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 831 | 0.270 |
Why?
|
| Referral and Consultation | 2 | 2019 | 308 | 0.260 |
Why?
|
| Biopsy | 3 | 2014 | 1132 | 0.250 |
Why?
|
| Male | 9 | 2022 | 39847 | 0.250 |
Why?
|
| Pandemics | 4 | 2022 | 630 | 0.240 |
Why?
|
| Time Factors | 5 | 2016 | 5177 | 0.230 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 487 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2018 | 2603 | 0.210 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1329 | 0.200 |
Why?
|
| Mammography | 2 | 2017 | 456 | 0.190 |
Why?
|
| Betacoronavirus | 2 | 2020 | 245 | 0.190 |
Why?
|
| Personnel Selection | 1 | 2020 | 52 | 0.190 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 215 | 0.190 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 954 | 0.190 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 59 | 0.190 |
Why?
|
| Health Resources | 1 | 2020 | 73 | 0.190 |
Why?
|
| Fear | 1 | 2019 | 67 | 0.190 |
Why?
|
| Triage | 1 | 2020 | 98 | 0.180 |
Why?
|
| Body Image | 1 | 2019 | 79 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 97 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2018 | 7608 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 261 | 0.180 |
Why?
|
| Breast Implants | 2 | 2016 | 21 | 0.180 |
Why?
|
| Interviews as Topic | 1 | 2020 | 315 | 0.180 |
Why?
|
| Anxiety | 1 | 2021 | 252 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2020 | 184 | 0.180 |
Why?
|
| Video Recording | 1 | 2019 | 187 | 0.170 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 4 | 0.170 |
Why?
|
| Databases as Topic | 1 | 2018 | 91 | 0.170 |
Why?
|
| Emotions | 1 | 2021 | 313 | 0.170 |
Why?
|
| Telemedicine | 1 | 2020 | 146 | 0.160 |
Why?
|
| Patient Participation | 1 | 2019 | 197 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2018 | 223 | 0.160 |
Why?
|
| Choice Behavior | 1 | 2018 | 155 | 0.160 |
Why?
|
| Heterozygote | 2 | 2016 | 360 | 0.160 |
Why?
|
| Sleep | 1 | 2021 | 428 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2018 | 652 | 0.150 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 176 | 0.150 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 83 | 0.150 |
Why?
|
| Disease Management | 1 | 2018 | 324 | 0.150 |
Why?
|
| Esthetics | 1 | 2016 | 49 | 0.150 |
Why?
|
| Watchful Waiting | 1 | 2016 | 51 | 0.150 |
Why?
|
| Illinois | 1 | 2017 | 452 | 0.150 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 191 | 0.150 |
Why?
|
| Neoplasms | 2 | 2022 | 2705 | 0.150 |
Why?
|
| Comprehension | 1 | 2016 | 68 | 0.140 |
Why?
|
| Molecular Typing | 1 | 2015 | 15 | 0.140 |
Why?
|
| Europe | 1 | 2016 | 304 | 0.140 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.140 |
Why?
|
| Remission Induction | 1 | 2017 | 709 | 0.140 |
Why?
|
| Physicians | 2 | 2019 | 609 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2016 | 221 | 0.140 |
Why?
|
| Counseling | 1 | 2016 | 138 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1726 | 0.140 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 53 | 0.130 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 880 | 0.130 |
Why?
|
| Linear Models | 1 | 2015 | 404 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 296 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1039 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1746 | 0.130 |
Why?
|
| Incidence | 2 | 2017 | 1553 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 429 | 0.130 |
Why?
|
| Adipokines | 1 | 2013 | 19 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 225 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2014 | 146 | 0.120 |
Why?
|
| Receptor, Notch4 | 2 | 2010 | 5 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 122 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 849 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2013 | 127 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 121 | 0.120 |
Why?
|
| Surgical Flaps | 1 | 2015 | 248 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2013 | 238 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 370 | 0.100 |
Why?
|
| Jagged-1 Protein | 1 | 2010 | 11 | 0.100 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 12 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2602 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1735 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1168 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1034 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 111 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2174 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 176 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2022 | 371 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 351 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 32 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2008 | 217 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 65 | 0.090 |
Why?
|
| Hemostatics | 1 | 2008 | 54 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2009 | 234 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 234 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 1047 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2008 | 144 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 358 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 154 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 164 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 173 | 0.080 |
Why?
|
| Obesity | 1 | 2013 | 929 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2008 | 904 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1942 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1187 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1946 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1171 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1625 | 0.060 |
Why?
|
| Mutation | 1 | 2014 | 3819 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 302 | 0.060 |
Why?
|
| Organizational Innovation | 1 | 2020 | 35 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1039 | 0.050 |
Why?
|
| Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 288 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2018 | 29 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 11 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 600 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 99 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 333 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2017 | 206 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 275 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 1346 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 736 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1545 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 440 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 271 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 402 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 112 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 150 | 0.030 |
Why?
|
| Serpins | 1 | 2013 | 26 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 21 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 321 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 60 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 100 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 673 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 581 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 59 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 94 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2013 | 123 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 73 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 349 | 0.030 |
Why?
|
| Sepsis | 1 | 2015 | 273 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 923 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2013 | 746 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.020 |
Why?
|
| Estradiol | 1 | 2008 | 248 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 442 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 764 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 539 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1041 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 10886 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 25907 | 0.010 |
Why?
|